HC Wainwright Reiterates Neutral Rating for Evommune (NYSE:EVMN)

Evommune (NYSE:EVMN)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports.

Several other analysts also recently commented on EVMN. Morgan Stanley decreased their target price on shares of Evommune from $55.00 to $26.00 and set an “overweight” rating for the company in a research report on Tuesday, June 30th. Raymond James Financial cut Evommune from a “strong-buy” rating to a “moderate buy” rating in a research report on Monday, June 29th. William Blair lowered shares of Evommune from an “outperform” rating to a “market perform” rating in a research report on Monday, June 29th. Wall Street Zen lowered Evommune from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Oppenheimer started coverage on Evommune in a research report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.62.

Evommune Stock Down 0.1%

NYSE:EVMN opened at $11.23 on Monday. The stock has a fifty day simple moving average of $17.00 and a 200 day simple moving average of $21.41. The firm has a market capitalization of $404.68 million and a price-to-earnings ratio of -1.18. Evommune has a 1-year low of $10.47 and a 1-year high of $33.20.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. Equities analysts predict that Evommune will post -2.83 earnings per share for the current year.

Insider Buying and Selling at Evommune

In other Evommune news, insider Janice Suzann Drew sold 20,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $22.63, for a total transaction of $452,600.00. Following the sale, the insider directly owned 67,794 shares of the company’s stock, valued at approximately $1,534,178.22. This represents a 22.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Luis C. Pena sold 7,438 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total transaction of $168,916.98. Following the sale, the chief executive officer directly owned 630,458 shares of the company’s stock, valued at approximately $14,317,701.18. The trade was a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 100,854 shares of company stock worth $2,279,142 over the last ninety days. Company insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Evommune

A number of large investors have recently bought and sold shares of the business. Capricorn Fund Managers Ltd acquired a new stake in Evommune during the 4th quarter valued at $1,027,000. China Universal Asset Management Co. Ltd. acquired a new position in Evommune in the fourth quarter worth $34,000. Sectoral Asset Management Inc. bought a new stake in shares of Evommune during the fourth quarter worth $10,084,000. Geode Capital Management LLC acquired a new stake in shares of Evommune in the fourth quarter valued at $1,881,000. Finally, Seven Grand Managers LLC acquired a new stake in shares of Evommune in the fourth quarter valued at $1,284,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.